

## Draft Guidance on Ivacaftor; Lumacaftor

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

**Active Ingredient:** Ivacaftor; Lumacaftor

**Dosage Form; Route:** Tablet; Oral

**Recommended Studies:** Two Studies

1. Type of study: Fasting  
Design: Single-dose, two-treatment, two-period crossover in vivo  
Strength: 125 mg Ivacaftor; 200 mg Lumacaftor  
(at a dose of 2 x 125 mg Ivacaftor; 200 mg Lumacaftor)  
Subjects: Males and non-pregnant, non-lactating females, general population  
Additional Comments: None

---

2. Type of study: Fed  
Design: Single-dose, two-treatment, two-period crossover in vivo  
Strength: 125 mg Ivacaftor; 200 mg Lumacaftor at a dose of (at a dose of 2 x 125 mg Ivacaftor; 200 mg Lumacaftor)  
Subjects: Males and non-pregnant, non-lactating females, general population  
Additional Comments: None

**Analytes to measure (in appropriate biological fluid):** Ivacaftor; lumacaftor in plasma

**Bioequivalence based on (90% CI):** Ivacaftor; lumacaftor

**Waiver request of in-vivo testing:** 125 mg; 100 mg based on (i) acceptable bioequivalence study on the 125 mg; 200 mg strength, (ii) proportionally similar formulation across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths

**Dissolution test method and sampling times:** The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website available to the public at the following location: <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).